Consumer diagnostics · Oral microbiome
Bristle Health
A saliva test that sequences the whole oral microbiome and sells the answer to consumers and to dental practices. Four years after its seed round, the accuracy claim still rests on a company white paper and a preprint written mostly by company employees.
A Reddit post, and a third co-founder
In 2020, two men who had spent their careers selling sequencing equipment decided to build a company around spit. They had the commercial half covered. They had no scientist.
Danny Grannick had studied biochemistry, then gone to Illumina, then to Oxford Nanopore. Brian Maurer, his co-founder, was the person everyone knows: fanatical about flossing, and still walking out of the dentist with a cavity.
It was the middle of the pandemic. No conferences, no way to bump into a microbiologist. So Grannick posted on Reddit asking how to meet a scientific co-founder, without describing the company. David Lin answered. He had a PhD in microbiology and immunology, and taught dental students.
“We met over coffee the next week, discussed Bristle, and our founding team was created two hours later.”
Bristle went into Y Combinator’s Winter 2021 batch. Company data lists a fourth co-founder, Shivam Patel.
The problem they picked
Dentistry is good at finding damage. An X-ray shows a cavity once the enamel has gone. A probe measures a pocket once the gum has lost attachment. Both measure the past.
“Our oral health is kind of a black box,” Grannick said when the seed round was announced.
The microbiology underneath is old and well documented. Streptococcus mutans turns sugar into acid that demineralises enamel. Porphyromonas gingivalis, Tannerella forsythia and Treponema denticola travel with periodontitis. Bristle’s white paper cites CDC figures that 47.2 percent of American adults over 30 have gum disease.
Knowing that bacteria drive these diseases is not the same as knowing that a bacterial census predicts them in one mouth, or that shifting the census shifts the outcome. That gap is where this company lives.
Who is running it
Grannick is chief executive. Lin is chief scientific officer and first author on the 2026 preprint. Maurer and Patel speak for the company in the 2025 and 2026 announcements. Y Combinator lists a team size of six.
What the test actually does
A kit arrives, the user spits into a tube holding a stabilising buffer, and mails it back. The lab starts sequencing every Monday, the run takes eight days, and reports land two to three weeks later.
The chemistry is in the 2022 white paper. DNA is extracted with a Zymobiomics kit, libraries are prepared in house and sequenced on an Illumina NovaSeq to at least five million paired end reads at 150 base pairs. Human reads are stripped out, and the rest is mapped against more than 30,000 bacterial reference genomes.
That is shotgun metagenomics, not the cheaper 16S method or the targeted qPCR panels dental labs such as OralDNA have sold since 2008. It buys species level resolution and picks up fungi. Bristle markets it as covering more than 800 species; other company pages put the figure at 700 or more.
The customer gets back seven scores: Beneficial Bacteria, Tooth Decay, Gum Inflammation, Halitosis, Gut Impact, Nitric Oxide and Diversity, plus a species list and product, diet and hygiene recommendations. The output is qualitative: abundances are percentages of a whole, not counts per millilitre.
The money, then the partners
Bristle announced a $3 million seed on May 24, 2022, led by Initialized Capital, with Y Combinator and 23andMe co-founder Anne Wojcicki. Axios reported it two months later.
“Bristle fills a knowledge & care gap that patients would never receive from the standard biannual dental visit,” said Parul Singh of Initialized.
Since then the public trail is partnerships rather than capital. A joint study with the University of the Pacific Dugoni School of Dentistry produced the accuracy figures. In December 2025 Bristle and Tiny Health opened recruitment for an oral and gut study. In July 2026 Bristle tied itself to Dentistry.One, the virtual dental arm of MouthWatch, adding coaches, teledental consults and a referral network behind the result.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| FDA record | No 510(k) and no premarket approval found in FDA device databases, checked Sep 23, 2026. The test is not FDA cleared, and the company does not claim it is. | Public record |
| Registered trials | No Bristle sponsored study in the trial registry. The Dugoni and Tiny Health work appears in announcements only. | Not found |
| Peer reviewed papers | None found in PubMed on company name, product name or author names as of Sep 23, 2026. | Not found |
| Accuracy claim | Company white paper, 2022: case control study of 100 adults at Dugoni, periodontal disease defined as any pocket deeper than 4mm. Reported AUC 0.88, 74% sensitivity, 85% specificity for gum disease; AUC 0.81, 69% and 75% for caries. Hosted on the help centre, not a journal, never replicated outside the company. | Company-stated |
| 2026 preprint | Posted to bioRxiv Jan 27, 2026: 220 saliva samples, more periodontal pathogens in gum disease, more cariogenic species in caries. Two of three authors declare they are Bristle employees. Reports associations, not diagnostic accuracy. Not peer reviewed. | Company-affiliated |
| Laboratory and CLIA | Company FAQs say Bristle tests are analysed in a U.S. laboratory that is certified by CLIA standards. The laboratory is not named and no certificate number is published. A practitioner marketplace listing adds CAP, ISO 15189 and COLA, none of it verifiable against a primary certificate. | Company-stated |
| How the framing moved | In 2021 the CEO placed the product in the wellness category, with clinical validation and an FDA submission still ahead. In 2026 the site sells root cause insight into tooth decay, gum inflammation, halitosis and oral fungi. No validation study or FDA record appeared in between. | Claim moved, record did not |
| Reimbursement | Provider FAQ: CDT codes exist, but most insurers do not reimburse salivary testing. $169 to consumers, practitioner pricing reported at $90 to $120, HSA and FSA eligible. | Company-stated |
| Category check | A 2026 NIST study sent one homogenised sample to seven consumer microbiome companies in triplicate. Species counts ran from under 100 to over 1,700, only three genera appeared in every sample, and one replicate returned a different health verdict than its twins. Gut services, anonymised. | Independent |
Read plainly: the biology under this product is real and decades old, and shotgun metagenomics is a better instrument than the 16S panels it competes with. What has never happened is an outside look at the test. The accuracy numbers come from 100 patients in a help centre document, and the nearest thing to a check is a preprint whose first two authors work for Bristle. That is not proof of a poor test. It is an absence of evidence.
“This study shows that the tests may not be analytically valid, let alone clinically valid.” said Diane E. Hoffmann of the University of Maryland Carey School of Law. A gastroenterologist told Medscape in 2024: “I explain to patients that these tests are not validated and are clinically meaningless data and not worth the money.” Both were talking about gut testing. Nobody has run that experiment on oral services, which is the point.
What to watch
- Whether the January 2026 preprint clears peer review, and whether the published version carries diagnostic accuracy rather than associations.
- Whether Bristle names the laboratory that performs its sequencing and publishes a CLIA certificate number.
- Any prospective test of the thing being sold: do people who act on a report have fewer new cavities two years on.
- A new financing. The last one on public record closed in 2022, and no Form D has ever been filed.
In their words
“We detect these bacteria before they have the opportunity to grow and cause irreversible damage,”
David Lin, CSO and co-founder, seed announcement, 2022 · Company release
“our test right now is operating in a wellness category where we’re not reporting on diagnosis of oral disease”
Danny Grannick, Our Longevity Futures podcast, Gowing Life, 2021 · Interview
“we’d like to pursue FDA approval on the test and the equivalent for other areas in the world”
Danny Grannick, same interview, 2021. No FDA record exists as of September 2026 · Interview
“Bristle fills a knowledge & care gap that patients would never receive from the standard biannual dental visit,”
Parul Singh, partner, Initialized Capital, 2022 · Investor, in company release
“the microbiome changes a lot from test to test, even if you think you’ve done nothing special”
Richard Sprague, after testing the product, proto.life, September 2022 · Independent
“I do hope this company doesn’t go down the route of ubiome, overstating the science and what the oral microbiome can do.”
Anonymous customer review, r/Microbiome, June 2022 · User report
Related companies
Sources
- Public recordFDA databases, trial registry, NIH RePORTER, NSF awards: no Bristle records
- Public recordSEC EDGAR company and full text search for Bristle: no filings
- Public recordPubMed searches on company, product and author names: nothing indexed
- Public recordSalivary microbiome diversity, oral health and disease
- IndependentAnalytical performance of direct-to-consumer gut microbiome testing services
- IndependentDirect-to-consumer microbiome tests prove wide variability
- IndependentAre DTC Microbiome Tests Clinically Useful?
- IndependentIt’s Now Possible to Track Your Oral Microbiome
- IndependentBristle polishes off $3M seed
- IndependentBristle profile, founders and funding
- InterviewMeet The Disruptors: Danny Grannick
- InterviewDanny Grannick, Our Longevity Futures, episode 3
- CompanyBristle Raises $3M for its At-Home Oral Microbiome Test
- CompanyBristle Oral Health Test White Paper
- CompanyProvider guide FAQ, plus home and product pages
- PartnerTiny Health and Bristle Health oral-gut study
- PartnerBristle Health and Dentistry.One partnership
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
